Revolutionizing Cancer Therapy

We aspire to create safe and effective therapies for cancer patients through the body’s own immune system.

Learn More About Our Therapeutics

Harnessing the Innate Immune System to Combat Checkpoint-Insensitive Tumors

Our lead candidate, AXA-042, is a novel systemically-delivered TLR2/6 agonist that drives anti-tumor response through engagement of the innate immune system.

Targeting a large unmet medical need in oncology

Re-awakening the innate immune system in cancer patients

Overcoming resistance to checkpoint blockade therapy

Generation of long-lasting response in solid tumour indications

Learn More About Our Lead Candidate

A Highly-Experienced Leadership Team in Oncology Drug Discovery

Meet The Team